Treaty pricing actuary must resolve whether to non-renew a deteriorating book

Situation

After a product that just got an FDA warning letter, umbrella underlying-limit adequacy memo is what treaty pricing actuary can touch in a fleet with a new ELD vendor and rising frequency. Insurance Underwriting will live with Bind versus Restrict on this Core Commercial Lines file.

Decision

Treaty pricing actuary in a fleet with a new ELD vendor and rising frequency must choose Bind / Restrict / Decline / Hold using umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter.

Hypotheses to test

• The population in umbrella underlying-limit adequacy memo is the one a product that just got an FDA warning letter named, so Bind follows for this Core Commercial Lines file.
• The population in umbrella underlying-limit adequacy memo is adjacent only to a product that just got an FDA warning letter; Restrict is the honest Insurance Underwriting call.
• A fleet with a new ELD vendor and rising frequency already contained a product that just got an FDA warning letter before umbrella underlying-limit adequacy memo arrived; no new Core Commercial Lines path.
• Provenance on umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter is broken; do not pick Bind or Restrict yet.

Analysis required

• Say whether a fleet with a new ELD vendor and rising frequency can bind, restrict, or decline from the file as it stands.
• Test exposure, limits, and endorsement language in umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter.
• Flag any accumulation fact umbrella underlying-limit adequacy memo does not price.
• For this Insurance Underwriting Core Commercial Lines file, read umbrella underlying-limit adequacy memo against a product that just got an FDA warning letter and write the one fact that would move to non-renew a deteriorating for treaty pricing actuary.

Recommendation

Choose Bind / Restrict / Decline / Hold on this Insurance Underwriting / Core Commercial Lines packet (umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter). If umbrella underlying-limit adequacy memo cannot force a Insurance Underwriting label under Core Commercial Lines, stop. If umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter cannot support Bind versus Restrict on this Insurance Underwriting Core Commercial Lines close, treaty pricing actuary must do not bind, restrict, or decline beyond what the submission actually prices.